Ricarda M. Hoffmann

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.

Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 12, 2023

B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma.

B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma.

Journal: Nature communications
Published: June 01, 2022

CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models.

CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models.

Journal: Cancers
Published: April 19, 2022

Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.

Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.

Journal: Nature communications
Published: April 08, 2022

B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.

B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.

Journal: Frontiers in immunology
Published: October 28, 2020

Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.

Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action.

Journal: European journal of immunology
Published: July 29, 2020

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs).

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs).

Journal: Scientific reports
Published: March 23, 2020

A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.

A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.

Journal: Cancers
Published: March 18, 2020

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.

Journal: Frontiers in immunology
Published: August 30, 2018

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 28, 2018

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).

Journal: Oncoimmunology
Published: September 15, 2017

BRAF inhibitors: resistance and the promise of combination treatments for melanoma.

BRAF inhibitors: resistance and the promise of combination treatments for melanoma.

Journal: Oncotarget
Published: June 16, 2017
Showing 1-12 of 13

Last Updated: 09/26/2026